Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Psychological Methods|September 9, 2010
The importance of covariate selection in controlling for selection bias in observational studiesPeter M Steiner, Thomas D Cook, William R Shadish, et al.
Clinical Trials (London, England)|April 1, 2025
Aspirin in primary prevention: Undue reliance on an uninformative trial led to misinformed clinical guidelinesJanet Wittes, David L DeMets, KyungMann Kim, et al.
JACC. Heart Failure|March 14, 2014
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2)Milton Packer, Peter Carson, Uri Elkayam, et al.
Psychological Methods|May 4, 2011
A randomized experiment comparing random and cutoff-based assignmentWilliam R Shadish, Rodolfo Galindo, Vivian C Wong, et al.
Circulation. Arrhythmia and Electrophysiology|January 13, 2018
Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION TrialMatthew M Kalscheur, Ryan T Kipp, Matthew C Tattersall, et al.
Heart Rhythm|March 22, 2017
Outcomes of cardiac resynchronization therapy in patients with intermittent atrial fibrillation or atrial flutter in the COMPANION trialMatthew M Kalscheur, Leslie A Saxon, Byron K Lee, et al.
Therapeutic Innovation & Regulatory Science|February 11, 2022
Ivermectin in COVID-19: The Case for a Moratorium on PrescriptionsAndreea Molnar, Stephanie Lau, Maja Berges, et al.
Contemporary Clinical Trials|March 18, 2022
The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE studyZhen Huang, Frank W Rockhold, W Schuyler Jones, et al.
Ultrasound in Medicine & Biology|April 16, 2020
Attenuation Coefficient Parameter Computations for Tissue Composition Assessment of Carotid Atherosclerotic Plaque in VivoCatherine N Steffel, Shahriar Salamat, Thomas D Cook, et al.
European Journal of Heart Failure|March 22, 2019
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)John J V McMurray, David L DeMets, Silvio E Inzucchi, et al.
Pageof 11